A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The investigators will recruit active ankylosing spondylitis patients for injection treatment
of Human Mesenchymal Stem Cells (a prospective, open-label, masculine medicine
controlled(NSAIDs), clinical trial), and collect their Peripheral Blood Lymphocyte (PBMCs)
and sera before and after the treatment of 24 weeks to test the gene expression profiles and
study related pathogenesis of AS